Kunlun Capital
VC Fund
Singapore, Singapore
Kunlun Capital is a value-oriented and fundamentally driven family office. We do not manage external funds.
- Total investments:
- 16
- Last investment:
- Lead investor:
- 19%
Last updated:
For AI agents: llms.txt
Industries Kunlun Capital invests in
Stages Kunlun Capital invests in
Countries Kunlun Capital invests in
Round sizes
Round size
- Seed
- $20M–$31M
- Series A
- $19M–$40M
Investment Focus
Industry
- Biotechnology 9 (56%)
- Health Care 4 (25%)
- Medical 3 (19%)
- Genetics 3 (19%)
- Biopharma 2 (13%)
Stage
- Series A 4 (25%)
- Seed 3 (19%)
- Series B 2 (13%)
- Angel 1 (6%)
- Series C 1 (6%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Hui-Gene is focused on R&D for single-gene disorders and has developed pilot pipes in neurodegenerative diseases. | Series C / May 12, 2022 | ||
| Ningbo Shanshan engaged in the research and development, manufacture and distribution of lithium battery materials. | $477M / Post-IPO Equity / Apr 19, 2022 | ||
| CellOrigin Biotech is a company committed to iPSC-derived innate immune cell therapeutics. | $15.7M / Venture - Series Unknown / Mar 29, 2022 | ||
| Inventing small molecule in the realm of drug discovery fostered by protein dynamics. | $40M / Series A / Mar 14, 2022 | ||
|
UniXell
|
UniXell develops cell therapies for the treatment of cancer and neurodegenerative disorders. | $31.4M / Seed / Mar 14, 2022 | |
| Zhongke Digital is a Chinese company that specializes in the development of dedicated computing architectures for finance, artificial intelligence, and blockchain. The company is based in Beijing. China. | Series A / Dec 21, 2021 | ||
| Ring Code Bio is a biomedical company that develops nucleic acid drugs based on a unique circular RNA technology platform. | $20M / Seed / Dec 16, 2021 | ||
CirCode
|
CirCode utilizes mRNA biotechnology to develop new biomedicine and drugs. | $20M / Seed / Dec 16, 2021 | |
| Danwang Medical is a research organization focusing on regenerative medicine and organoid technology. | $18.6M / Series A / Oct 14, 2021 | ||
|
UniXell
|
UniXell develops cell therapies for the treatment of cancer and neurodegenerative disorders. | Angel / Aug 01, 2021 | |
| See all 16 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Kunlun Capital invest in?
Kunlun Capital invests primarily in Biotechnology, Health Care and Medical startups, most often at Series A and Seed stage. Most of the 16 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What round sizes does Kunlun Capital invest in?
Kunlun Capital typically joins rounds of $20M–$31M at Seed and $19M–$40M at Series A. These are whole funding-round sizes, not Kunlun Capital's own check, which is rarely disclosed: the 10th–90th percentile of the confirmed public funding rounds Kunlun Capital took part in.
When did Kunlun Capital last invest?
The most recent investment recorded for Kunlun Capital closed in May 2022. Shizune tracks 16 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
